BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published on February 20
This patent battle could reshape the entire mRNA vaccine industry. The outcome will determine which companies control the most valuable intellectual property in modern medicine.
While BioNTech and Moderna are tied up in court, smaller biotech companies with alternative vaccine technologies could seize their moment to shine and capture market share.
This group includes companies developing protein-based, DNA-based, and even oral vaccines. These alternative approaches could become the next big breakthrough in vaccine technology.
This legal battle between two mRNA giants creates uncertainty that could reshape the entire vaccine industry. While BioNTech and Moderna fight over patent rights, other companies with different vaccine technologies may find new opportunities to advance their programmes and capture market share from the distracted leaders.
This collection includes companies across various vaccine technologies - from traditional approaches to innovative delivery methods. The group spans both the main litigants and their potential beneficiaries, representing different risk levels and growth opportunities in the evolving biotech landscape.
Our analysts selected these companies based on their strategic positioning during this patent dispute. Each has been chosen for their potential to either weather the legal storm or capitalise on the market disruption, representing both established pharmaceutical giants and innovative biotech pioneers.
This basket's total market capitalisation is 1,644,529.9998; it is heavily anchored by a few very large-cap stocks, which tends to produce a comparatively stable profile.
MRNA: $19.42B
BNTX: $28.60B
PFE: $152.72B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+78.09%
On average, analysts expect assets in this group to grow 78.09% over the next year.
10 of 14 assets in this group are rated Buy by professional analysts.
